Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: "John C van Swieten" Clear advanced filters

  • Alzheimer disease (AD) biomarkers reflect specific features of AD pathology. These biomarkers may be used in the diagnosis and staging of AD, or may act as surrogate end points in clinical trials. Thus, a thorough understanding of the diagnostic accuracy of and longitudinal change in cerebrospinal fluid and MRI AD biomarkers is important.

    • Niels D. Prins
    • John C. van Swieten
    News & Views
    Nature Reviews Neurology
    Volume: 6, P: 650-651

  • Reliable biomarkers for frontotemporal dementia (FTD) are required for accurate discrimination between dementia types, prediction of clinical progression and tailoring of pharmacological interventions. This Review discusses the increasing number of available biomarkers for FTD — including novel imaging modalities and fluid biomarkers — and the future challenges in their implementation.

    • Lieke H. Meeter
    • Laura Donker Kaat
    • John C. van Swieten
    Reviews
    Nature Reviews Neurology
    Volume: 13, P: 406-419